Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

Condition:   Primary Central Nervous System Lymphoma Interventions:   Drug: Orelabrutinib;   Drug: Pomalidomide;   Drug: Rituximab;   Drug: Methotrexate Sponsors:   Peking Union Medical College Hospital;   Beijing Tiantan Hospital;   Sanbo Brain Hospital Capital Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials